Company intelligence / Profile preview

BioStatus

Loughborough, Leicestershire, United Kingdombiostatus.com ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

BioStatus has developed a suite of innovative far-red fluorescent DNA dyes—most notably the DRAQ™ series—used worldwide for cell analysis. Their products are widely adopted in imaging, cytometry, drug discovery research, clinical diagnostics, and routine laboratory workflows. The company has received industry recognition for innovation but does not conduct therapeutic clinical trials itself.

Therapeutic areas: Other
Modalities: Reagent (for cell-based analysis)Diagnostic reagent (in vitro diagnostic reagents)Fluorescent dye (e.g., DRAQ7™)Small molecule (as the dyes are small molecules)
Industry: Chemicals & Materials

Drug pipeline

2 assets

DRAQ5

Commercial

Indications: Cell analysis, DNA staining

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioStatus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioStatus.

Explore the full profile